Free Trial

Versigent (NYSE:VGNT) Releases Quarterly Earnings Results

Versigent logo with background
Image from MarketBeat Media, LLC.

Key Points

  • Versigent reported quarterly EPS of $999.00, a striking figure disclosed in its latest results.
  • Shares traded up $1.31 to $37.48 on Tuesday with about 1.8M shares changing hands (below the ~3.59M average); the 12‑month range is $26.34 to $37.68.
  • Analysts give a consensus "Moderate Buy" with a mean price target of $42.13 after several firms initiated coverage (targets range roughly $35–$47 and ratings include 1 Strong Buy, 6 Buy, 3 Hold).
  • MarketBeat previews the top five stocks to own by June 1st.

Versigent (NYSE:VGNT - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $999.00 EPS for the quarter, Zacks reports.

Versigent Price Performance

Shares of NYSE VGNT traded up $1.31 during midday trading on Tuesday, hitting $37.48. 1,805,289 shares of the company's stock were exchanged, compared to its average volume of 3,587,132. Versigent has a 12-month low of $26.34 and a 12-month high of $37.68.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. TD Cowen began coverage on shares of Versigent in a report on Tuesday, April 14th. They set a "buy" rating and a $47.00 target price on the stock. Wall Street Zen upgraded Versigent to a "hold" rating in a research report on Saturday, April 18th. UBS Group started coverage on Versigent in a research note on Tuesday, April 14th. They set a "buy" rating and a $43.00 price objective on the stock. Wells Fargo & Company began coverage on Versigent in a report on Monday, April 6th. They set an "overweight" rating and a $35.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft started coverage on Versigent in a report on Tuesday, April 28th. They set a "hold" rating and a $35.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Versigent presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.13.

Read Our Latest Analysis on VGNT

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Versigent Right Now?

Before you consider Versigent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Versigent wasn't on the list.

While Versigent currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines